Michael Levin, University of Saskatchewan

Research

multiple sclerosis neurodegeneration optogenetics bioinformatics computational modeling molecular dynamics peptide:protein dynamics hnRNP A1 RNA binding protein proteinopathy

Latest papers

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.
Signal transduction and targeted therapy · 2026
Health Canada Drug Approval Process: A Barrier to Personalized Care in Multiple Sclerosis.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2024
Participants' perspectives of "NeuroSask: Active and Connect"-a virtual chronic disease management program for individuals with a neurological condition.
Frontiers in neurology · 2024

All 4 publications

Latest funding

Investigating the molecular mechanisms of synaptic pathology in multiple sclerosis through dysfunction of heterogeneous nuclear ribonucleoprotein A1
CIHR · 2025 · Supervisor
$120,000
An innovative approach designed to disrupt RNA binding protein aggregation and attenuate neurodegeneration in multiple sclerosis
SSHRC · 2020 · Principal investigator
$250,000
Inhibition of Neuronal Endocytosis of IgG as a Therapy to Attenuate Neurodegeneration in a Model of Multiple Sclerosis
CIHR · 2020 · Supervisor
$105,000

All 3 grants and awards

4 publications.

01

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.

Price JDW, Vizeacoumar FS, Abuhussein O, Maranda V, Zhang Y, Adachi H, Nguyen K, Kyrylenko L, Rangel-Pozzo A, Dong H, Gong L, Materi A, Walke P, Ganapathysamy A, Denomy C, Freywald T, Dahiya R, Elhasasna H, Saxena A, Vizeacoumar JP, Patel H, Rajamanickam K, de Oliveira DM, Lazell-Wright M, Morales AM, Aggarwal A, Xu JL, Alli N, Munhoz EP, Gao P, Salsman J, Dahiya DK, Kola NS, Gonzalez-Lopez C, Thibault P, Levin M, Dellaire G, Jette N, Groot G, Köbel M, Lee CH, Hopkins L, Krishnan A, Ahmed S, Eskiw C, Barakat KH, Thakur A, Wu Y, DePinho RA, Mai S, Yu YT, Wong JMY, Freywald A, Vizeacoumar FJ

Signal transduction and targeted therapy2026

DOI: 10.1038/s41392-026-02750-0 PMID: 42236690

02

Health Canada Drug Approval Process: A Barrier to Personalized Care in Multiple Sclerosis.

Oh J, Bhan V, Traboulsee A, Morrow SA, Lee L, Levin M, Casserly C, Freedman MS, Giacomini PS, Émond F, Smyth P, Clift F, Selchen D

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques2024

DOI: 10.1017/cjn.2024.267 PMID: 38777804

03

Participants' perspectives of "NeuroSask: Active and Connect"-a virtual chronic disease management program for individuals with a neurological condition.

Patrick SE, Knox KB, Evans C, Levin M, Linassi G, Poliakov I, Rajput A, Donkers SJ

Frontiers in neurology2024

DOI: 10.3389/fneur.2024.1332859 PMID: 38327624

04

Translingual neurostimulation combined with physical therapy to improve walking and balance in multiple sclerosis (NeuroMSTraLS): Study protocol for a randomized controlled trial.

Ploughman M, Melam GR, Buragadda S, Lohse KR, Clift F, Stefanelli M, Levin M, Donkers SJ

Contemporary clinical trials2023

DOI: 10.1016/j.cct.2023.107142 PMID: 36878390

Investigating the molecular mechanisms of synaptic pathology in multiple sclerosis through dysfunction of heterogeneous nuclear ribonucleoprotein A1

SupervisorCIHR2025DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Principal investigators: Messmer, Miranda L

Keywords: Confocal Microscopy; Crispr; Heterogeneous Nuclear Ribonucleoprotein A1; Multiple Sclerosis; Neurodegeneration; Neurological Disease; Neuroscience; Rna Binding Protein; Rna Sequencing; Synapse

$120,000

An innovative approach designed to disrupt RNA binding protein aggregation and attenuate neurodegeneration in multiple sclerosis

Principal investigatorSSHRC2020New Frontiers in Research Fund - Exploration

Principal investigators: Levin, Michael

Keywords: multiple sclerosis neurodegeneration optogenetics bioinformatics computational modeling molecular dynamics peptide:protein dynamics hnRNP A1 RNA binding protein proteinopathy

$250,000

Inhibition of Neuronal Endocytosis of IgG as a Therapy to Attenuate Neurodegeneration in a Model of Multiple Sclerosis

SupervisorCIHR2020Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Libner, Cole D

Keywords: Autoimmunity; Experimental Autoimmune Encephalomyelitis; Heterogenous Nuclear Ribonucleoprotein A1; Multiple Sclerosis; Neurodegeneration; Rna Binding Proteins

$105,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Department of Anatomy, Physiology, and Pharmacology
Oncology
Vaccine and Infectious Disease Organization
Medicine/Neurology
Food and Bioproduct Sciences
Community Health and Epidemiology
Pathology
Other

Applying for

Paper to mentionMention their SSHRC grant from 2020

Subject: Prospective PhD student: multiple sclerosis neurodegeneration optogenetics bioinformatics computational modeling molecular dynamics peptide:protein dynamics hnRNP A1 RNA binding protein proteinopathy Dear Professor Levin, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your SSHRC-funded project "An innovative approach designed to disrupt RNA binding protein aggregation and attenuate neurodegeneration in multiple sclerosis" (2020), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]